[1. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092.10.1056/NEJMoa1402582]Search in Google Scholar
[2. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13-19.10.1016/j.ejps.2014.02.014]Search in Google Scholar
[3. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res. 2016;118:1021-1040.10.1161/CIRCRESAHA.115.306565]Search in Google Scholar
[4. Su MY, Lin LY, Tseng YH, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014;7:991-997.10.1016/j.jcmg.2014.04.022]Search in Google Scholar
[5. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010;7:1438-1445.10.1016/j.hrthm.2010.04.030]Search in Google Scholar
[6. Li C, Han R, Kang L, et al. Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis. Sci Rep. 2017;7:40523.10.1038/srep40523]Search in Google Scholar
[7. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol. 2002;135:961-968.10.1038/sj.bjp.0704539]Search in Google Scholar
[8. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve. 2006;34:327-334.10.1002/mus.20590]Search in Google Scholar
[9. Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013;126:1-11.10.1159/000351179]Search in Google Scholar
[10. Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur J Heart Fail. 2018;20:1385-1391.10.1002/ejhf.1286]Search in Google Scholar
[11. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.10.1056/NEJM197112232852601]Search in Google Scholar
[12. Baek S, Park SH, Won E, et al. Propensity Score Matching: A Conceptual Review for Radiology Researchers. Korean J Radiol. 2015;16:286-296.10.3348/kjr.2015.16.2.286]Search in Google Scholar
[13. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321-1360.10.1093/ehjci/jew082]Search in Google Scholar
[14. Mohammed SF, Redfield MM. Response to Letters Regarding Article, “Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction”. Circulation. 2015;132:e206.10.1161/CIRCULATIONAHA.115.017050]Search in Google Scholar
[15. Lewis GA, Schelbert EB, Naish JH, et al. Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. Cardiovasc Drugs Ther. 2019.10.1007/s10557-019-06876-y]Search in Google Scholar